GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanologica AB (OSTO:NICA) » Definitions » EBIT

Nanologica AB (OSTO:NICA) EBIT : kr-58.90 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Nanologica AB EBIT?

Nanologica AB's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was kr-11.74 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-58.90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nanologica AB's annualized ROC % for the quarter that ended in Dec. 2024 was -45.90%. Nanologica AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -202.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nanologica AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -46.34%.


Nanologica AB EBIT Historical Data

The historical data trend for Nanologica AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanologica AB EBIT Chart

Nanologica AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.72 -41.60 -50.22 -69.45 -58.90

Nanologica AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.47 -15.30 -9.72 -22.15 -11.74

Competitive Comparison of Nanologica AB's EBIT

For the Biotechnology subindustry, Nanologica AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nanologica AB's EV-to-EBIT falls into.


;
;

Nanologica AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-58.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanologica AB  (OSTO:NICA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nanologica AB's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-47.568 * ( 1 - 0% )/( (122.035 + 85.235)/ 2 )
=-47.568/103.635
=-45.90 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nanologica AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-46.944/( ( (16.433 + max(-79.51, 0)) + (14.399 + max(15.621, 0)) )/ 2 )
=-46.944/( ( 16.433 + 30.02 )/ 2 )
=-46.944/23.2265
=-202.11 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.5 + 19.353 + -7.105427357601E-15) - (14.069 + 0 + 85.294)
=-79.51

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.896 + 32.745 + 0.00099999999999056) - (13.103 + 0 + 4.918)
=15.621

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nanologica AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-58.902/127.096
=-46.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanologica AB EBIT Related Terms

Thank you for viewing the detailed overview of Nanologica AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanologica AB Business Description

Traded in Other Exchanges
N/A
Address
Forskargatan 20G, Sodertalje, SWE, SE-151 36
Nanologica AB develops and manufactures nanoporous silica particles for life science applications. It focuses on two areas: Drug Development and Chromatography. The company's drug delivery platforms are NLAB Spiro and NLAB Silica, which focus on producing medicines for the benefit of patients. Its geographical segments are Sweden, China, India, the United States, and the Rest of the world.

Nanologica AB Headlines

No Headlines